Archives of Clinical Infectious Diseases

Published by: Kowsar

Lipoglycopeptide Antibiotics: Reliable Fighters Against Gram-Positive Pathogens

Haleh Bagheri 1 , Bahram Sohrabi 2 , Sara Salarian 3 and Bahador Bagheri 4 , *
Authors Information
1 Department of Pharmacology, Faculty of Medicine, CHU Toulouse, 31000-France
2 Department of Cardiovascular Diseases, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Intensive Care, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Cancer Research Center and Department of Pharmacology, Semnan University of Medical Sciences, Semnan, Iran
Article information
  • Archives of Clinical Infectious Diseases: December 31, 2018, 13 (6); e59526
  • Published Online: October 9, 2018
  • Article Type: Review Article
  • Received: August 6, 2017
  • Revised: July 19, 2018
  • Accepted: August 12, 2018
  • DOI: 10.5812/archcid.59526

To Cite: Bagheri H, Sohrabi B, Salarian S , Bagheri B. Lipoglycopeptide Antibiotics: Reliable Fighters Against Gram-Positive Pathogens, Arch Clin Infect Dis. 2018 ; 13(6):e59526. doi: 10.5812/archcid.59526.

Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Literature Search
2. Conclusions
  • 1. Allen NE, LeTourneau DL, Hobbs JN, Jr. Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother. 1997;41(1):66-71. [PubMed: 8980756]. [PubMed Central: PMC163661].
  • 2. Allen NE, LeTourneau DL, Hobbs JN, Jr. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J Antibiot (Tokyo). 1997;50(8):677-84. doi: 10.7164/antibiotics.50.677. [PubMed: 9315081].
  • 3. Allen NE, LeTourneau DL, Hobbs JN, Jr, Thompson RC. Hexapeptide derivatives of glycopeptide antibiotics: Tools for mechanism of action studies. Antimicrob Agents Chemother. 2002;46(8):2344-8. doi: 10.1128/AAC.46.8.2344-2348.2002. [PubMed: 12121903]. [PubMed Central: PMC127376].
  • 4. Nicolaou KC, Boddy CN, Brase S, Winssinger N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew Chem Int Ed Engl. 1999;38(15):2096-152. doi: 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F. [PubMed: 10425471].
  • 5. Thaker MN, Wright GD. Opportunities for synthetic biology in antibiotics: Expanding glycopeptide chemical diversity. ACS Synth Biol. 2015;4(3):195-206. doi: 10.1021/sb300092n. [PubMed: 23654249]. [PubMed Central: PMC4384835].
  • 6. Kalan L, Perry J, Koteva K, Thaker M, Wright G. Glycopeptide sulfation evades resistance. J Bacteriol. 2013;195(1):167-71. doi: 10.1128/JB.01617-12. [PubMed: 23104813]. [PubMed Central: PMC3536170].
  • 7. Cooper MA, Williams DH. Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium. Chem Biol. 1999;6(12):891-9. doi: 10.1016/S1074-5521(00)80008-3. [PubMed: 10631517].
  • 8. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: A comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs. 2006;7(8):740-9. [PubMed: 16955686].
  • 9. Jeya M, Moon HJ, Lee KM, Kim IW, Lee JK. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Curr Pharm Biotechnol. 2011;12(8):1194-204. doi: 10.2174/138920111796117382. [PubMed: 21470154].
  • 10. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26(5):511-32. doi: 10.1111/j.1574-6976.2003.tb00628.x. [PubMed: 12586393].
  • 11. Belley A, Harris R, Beveridge T, Parr TR, Moeck G. Differential targeting of cell wall assembly systems by oritavancin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17–20 September 2007; Chicago, IL. Washington, DC. ASM Press; 2007.
  • 12. Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. [PubMed: 18258256]. [PubMed Central: PMC2276640].
  • 13. Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369-71. doi: 10.1128/AAC.00760-10. [PubMed: 20876372]. [PubMed Central: PMC2981232].
  • 14. Saravolatz LD, Stein GE, Johnson LB. Telavancin: A novel lipoglycopeptide. Clin Infect Dis. 2009;49(12):1908-14. doi: 10.1086/648438. [PubMed: 19911938].
  • 15. Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis. 2012;54 Suppl 3:S203-13. doi: 10.1093/cid/cir923. [PubMed: 22431850].
  • 16. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260-3. doi: 10.1128/AAC.01453-08. [PubMed: 19124664]. [PubMed Central: PMC2650578].
  • 17. Gander S, Kinnaird A, Finch R. Telavancin: In vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother. 2005;56(2):337-43. doi: 10.1093/jac/dki198. [PubMed: 15972312].
  • 18. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: From conventional molecules to new derivatives. Drugs. 2004;64(9):913-36. doi: 10.2165/00003495-200464090-00001. [PubMed: 15101783].
  • 19. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30(1):80-94. doi: 10.1592/phco.30.1.80. [PubMed: 20030476].
  • 20. Arhin FF, Draghi DC, Pillar CM, Parr TR, Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4762-71. doi: 10.1128/AAC.00952-09. [PubMed: 19738026]. [PubMed Central: PMC2772347].
  • 21. Badal R, Bouchillon S, Hoban D, Hawser S, Johnson A, Hackel M. A multicenterevaluation of in vitro activity of oritavancin and comparators againststaphylococci, enterococci and streptococci-the Orion study. 19th European Congress on Clinical Microbiology and Infectious Diseases. 16–19 May 2009; Helsinki, Finland. Basel, Switzerland. European Society of Clinical Microbiology and Infectious Diseases; 2009.
  • 22. Arhin FF, Kurepina N, Sarmiento I, Parr TR, Jr, Moeck G, Kreiswirth B. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents. 2010;35(1):93-4. doi: 10.1016/j.ijantimicag.2009.07.012. [PubMed: 19744836].
  • 23. US Food and Drug Administration. Oritavancin for the treatment of complicatedskin and skin structure infections. US FDA briefing document for Anti-Infective Drugs Advisory Committee Meeting November 19, 2008; 2008, [5 February 2010]. Available from:
  • 24. Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53(3):918-25. doi: 10.1128/AAC.00766-08. [PubMed: 19104027]. [PubMed Central: PMC2650528].
  • 25. Targanta Therapeutics Corporation. NUVOCID® (oritavancindiphosphateforinjection) for treatment of complicated skin and skin structure infections. NDA 22-153. US FDA Briefing document for the Anti-Infective Drugs Advisory Committee November 19, 2008; 2008, [5 February 2010]. Available from:
  • 26. Wasilewski MM, Disch DP, McGill JM, Harris HW, O'Riordan WD, Zeckel ML. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 16–19 December 2001; Chicago, IL. Washington, DC. ASMPress; 2001.
  • 27. Giamarellou H, O'Riordan WD, Harris H, Owen S, Porter S, Loutit JS. Phase III trialcomparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexinin the treatment of patients with complicated skin and skin structure infections(CSSI). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14–17 September 2003; Chicago, IL. Washington, DC. ASM Press; 2003.
  • 28. Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365-72. doi: 10.1128/AAC.00176-15. [PubMed: 25824211]. [PubMed Central: PMC4432154].
  • 29. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180-90. doi: 10.1056/NEJMoa1310422. [PubMed: 24897083].
  • 30. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-79. doi: 10.1056/NEJMoa1310480. [PubMed: 24897082].
  • 31. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298-303. doi: 10.1086/379015. [PubMed: 14583862].
  • 32. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407-15. doi: 10.1086/497271. [PubMed: 16231250].
  • 33. Dunbar LM, Milata J, McClure T, Wasilewski MM; Simplifi Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: An analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55(7):3476-84. doi: 10.1128/AAC.00029-11. [PubMed: 21537018]. [PubMed Central: PMC3122413].
  • 34. Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, et al. Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting. Infect Dis Ther. 2016;5(3):353-61. doi: 10.1007/s40121-016-0119-9. [PubMed: 27370913]. [PubMed Central: PMC5019975].
  • 35. Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, et al. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2016;48(5):528-34. doi: 10.1016/j.ijantimicag.2016.07.019. [PubMed: 27665522].
  • 36. US National Library of Medicine. Open-label, dose-finding, pharmacokinetics, safety and tolerability study of oritavancin in pediatric patients with suspected or confirmed bacterial infections. NIH; 2010. Available from:
  • 37. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52(1):31-40. doi: 10.1093/cid/ciq031. [PubMed: 21148517]. [PubMed Central: PMC3060890].
  • 38. Corey GR, Stryjewski ME, O'Riordan WD, The ATLAS Study Group . ATLAS 1: The first phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections. 17th European Congress of Clinical Microbiology and Infectious Diseases. March 31–April 4, 2007; Munich, Germany. 2007.
  • 39. Corey GR, Stryjewski ME, Fowler VG, Jr, The ATLAS Study Group . ATLAS 2: A double-blind, randomised, active controlled, multinational phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections. 17th European Congress of Clinical Microbiology and Infectious Diseases. March 31–April 4, 2007; Munich, Germany. 2007.
  • 40. Steele JM, Seabury RW, Hale CM, Mogle BT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018;43(1):101-3. doi: 10.1111/jcpt.12580. [PubMed: 28628223].
  • 41. Delaportas DJ, Estrada SJ, Darmelio M. Successful treatment of methicillin susceptible staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy. 2017;37(8):e90-2. doi: 10.1002/phar.1957. [PubMed: 28543367].
  • 42. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50(2):95-102. doi: 10.1016/j.diagmicrobio.2004.06.007. [PubMed: 15474317].
  • 43. Bhavnani S, Rubino C, Forrest A, Lehoux D, Okusanya OO, Drusano GL. Use of pharmacokinetic-pharmacodynamic (PK-PD) principles to guide clinicaldrug development for oritavancin (ORI). 47th Interscience Conferenceon Antimicrobial Agents and Chemotherapy (ICAAC). 17–20 September 2007; Chicago, IL. Washington, DC. ASM Press; 2007.
  • 44. Moriarty SR, Wasilewski MM, Rosen AS, Perry M. Safety of oritavancinversusvancomycin for treatment of patients with complicated skin and skin-structureinfections. 19th European Congress of Clinical Microbiology and InfectiousDiseases (ECCMID). Helsinki, Finland. Basel, Switzerland. European Society of Clinical Microbiology and Infectious Diseases; 2009.
  • 45. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862-7. doi: 10.1128/AAC.50.3.862-867.2006. [PubMed: 16495243]. [PubMed Central: PMC1426424].
  • 46. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940-5. doi: 10.1128/AAC.48.3.940-945.2004. [PubMed: 14982787]. [PubMed Central: PMC353075].
  • 47. Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55 Suppl 2:ii25-30. doi: 10.1093/jac/dki008. [PubMed: 15750034].
  • 48. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465-76. doi: 10.1177/0091270008330162. [PubMed: 19318696].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments